AdvisorShares Pure Cannabis ETF

Tilray Brands' stock price rises with mixed analyst ratings

Jazz Pharmaceuticals Director O'Keefe Sold 603 Shares of Company Stock

TD Cowen Maintains Buy Rating on Tilray and Adjusts Price Target

Tilray Brands Launches Ultimate 2025 Holiday Beverage Gift Guide

Jazz Pharmaceuticals to Present Ziihera® Phase 3 Trial Results at ASCO GI 2026

Tilray Brands stock reached new 52-week high

Bruce C Cozadd sold 77,500 shares of Jazz Pharmaceuticals

Tilray Brands' stock price rose to $1.03

Tilray Brands Shares Rise as Analyst Ratings Diverge

Jazz Pharmaceuticals Director Heather Ann McSharry Sells Shares

Tilray Brands Inc. Launches Cannabis Vape Products in Quebec

UBS Analyst Maintains Hold Rating on Jazz Pharma

Jazz Pharmaceuticals Director Sells Ordinary Shares

Jazz Pharmaceuticals VP Exercises Options and Sells Shares

Jazz Pharmaceuticals EVP Robert Iannone Sold Company Shares

Wells Fargo Raises Jazz Pharmaceuticals Price Target to $235

FactSet Survey: Analysts Raise Target Price Estimate for Jazz Pharmaceuticals

Tilray Brands Announces a Release

Tilray Brands Inc Forecasts FY2023 Adjusted EBITDA of $62-72 Million

Jazz Pharma Announces Positive Results for Ziihera Clinical Trial

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

TLRY

Tilray Brands (NASDAQ:TLRY) shares rose 2.3% to $7.22, with trading volume up 77% from the average. Analysts have mixed ratings: ATB Cap Markets downgraded to "strong sell," Jefferies raised the target to $20 with a "buy" rating, and Wall Street Zen upgraded to "hold." The stock has a "Hold" consensus with a $20 target price. Institutional investors have increased their stakes. Tilray engages in medical cannabis distribution globally.

Market Beat

Tilray Brands

Tilray Brands (NASDAQ:TLRY) Trading Up 2.3%  - Still a Buy?

JAZZ

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc surrendered 603 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on December 4, 2025, at a price of $173.07 per share, totaling $104,361. O'Keefe's ending holdings are 30,256 shares, with 25,811 direct and 4,445 indirect.

Reuters

Jazz Pharma

Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ]

Tilray Brands Inc. (TLRY) shares rose 2.27% to $7.22 on Thursday, outperforming the NASDAQ Composite Index, which rose 0.22%, and the Dow Jones Industrial Average, which fell 0.07%. This rise ended a four-day losing streak. The stock is 68.88% below its 52-week high of $23.20. Trading volume was 8.9 million, above the 50-day average of 7.8 million.

Dow Jones

Tilray Brands Inc. Stock Rises Thursday, Outperforms Market

It may be time for investors to cut their losses.

Is there a future for Tilray Brands?

09:39 AM EST - Tilray Brands, Inc. : Today released its 2025 Cannabis Holiday Gift Guide, showcasing Canadians’ top picks for gifting, entertaining, and seasonal celebrations. Tilray Brands, Inc. shares T.TLRY are trading unchanged at $9.86.

Baystreet

Stocks in Play: Tilray Brands, Inc.

Robert Moskow from TD Cowen maintains a Buy rating on Tilray, adjusting the price target to $10 due to a reverse stock split. The valuation considers a lower enterprise value to EBITDA multiple of 12x, reflecting market challenges in craft beer and Canadian sectors. Despite these challenges, Moskow remains cautiously optimistic about Tilray's financial performance.

Tip Ranks

Strategic Valuation Adjustment and Optimistic Outlook for Tilray Amid Market Challenges

Tilray Brands Inc. shares fell 8.43% to $7.06 on Wednesday, marking the fourth consecutive day of losses. Despite a positive trading session for the NASDAQ and Dow Jones, Tilray's stock remains 69.57% below its 52-week high of $23.20. Trading volume reached 8.7 million, surpassing the 50-day average of 7.6 million.

Tilray Brands Inc. Stock Falls Wednesday, Underperforms Market

Tilray Brands (NASDAQ:TLRY) shares fell 1.5% during mid-day trading, with increased trading volume. Analysts have mixed ratings: two Buy, three Hold, and two Sell. Jefferies raised the price target to $20.00 with a Buy rating. Hedge funds have adjusted their holdings, and the stock has a consensus Hold rating with an average price target of $20.00.

Tilray Brands (NASDAQ:TLRY) Trading Down 1.5%  - What's Next?

Tilray Brands Inc. (TLRY) shares fell 1.46% to $7.71 on Tuesday, underperforming the market despite favorable trading conditions. This marks the stock's third consecutive day of losses, closing 66.77% below its 52-week high of $23.20. Trading volume was 9.0 million, above the 50-day average of 7.6 million.

Tilray Brands Inc. Stock Falls Tuesday, Underperforms Market

Jazz Pharmaceuticals announced positive Phase 3 results for Ziihera in HER2-positive gastroesophageal cancer. The study showed significant improvements in progression-free survival and overall survival with Ziihera combinations, compared to the control arm. Results will be presented at the 2026 ASCO GI Symposium.

Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Tilray Brands (TSE:TLRY) stock reached a new 52-week high, trading as high as C$10.99. Despite its growth, analysts suggest other stocks may be better buys. Tilray has a market cap of C$12.98 billion and a PE ratio of -4.62. The company, a major player in the cannabis market, has a Hold rating among analysts.

Tilray Brands (TSE:TLRY) Hits New 1-Year High  - Should You Buy?

Trading in shares of Tilray Brands Inc. (TSX: TLRY) has been temporarily halted by the Canadian Investment Regulatory Organization (CIRO) on the Toronto Stock Exchange due to a Single Stock Circuit Breaker. The halt was initiated at 10:52 AM ET to ensure a fair and orderly market.

Tilray Brands Trading Halted on TSX by CIRO

03:28 AM EST, 12/02/2025 (MT Newswires) -- Bruce C Cozadd, Director, on November 26, 2025, sold 77,500 shares in Jazz Pharmaceuticals ( JAZZ ) for $13,780,337. Following the Form 4 filing with the SEC, Cozadd has control over a total of 393,332 ordinary shares of the company, with 393,332 shares held directly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc filed a Form 144 with the SEC to sell 1,249 shares on December 1, 2025. The sale is planned for December 2, 2025, through E-TRADE Financial. Form 144 is required for selling restricted stock within 90 days of filing.

Dir O'Keefe Files To Sell 1,249 Of Jazz Pharmaceuticals Plc [JAZZ]

Cozadd Bruce C Chairman of the Board of Jazz Pharmaceuticals Plc [JAZZ] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:DateTransactionSharesPriceValue11/26/25Exercise(1) 77,500$123.36$9,560,40011/26/25Sale77,500$177.81$13,780,337Ending Holdings: 393,332 - Direct(1) Exercised 3.0 months before expiration date.For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.